Cardiometabolic risk in psoriasis: differential effects of biologic agents
Mariana J KaplanDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USAAbstract: Psoriasis is associated to an increased risk of cardiovascular (CV) complications. Overall, the pathogenic mechanisms involved in premature CV complications in psoriasis appear t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-12-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cardiometabolic-risk-in-psoriasis-differential-effects-of-biologic-age-peer-reviewed-article-VHRM |
| _version_ | 1819232263682916352 |
|---|---|
| author | Mariana J Kaplan |
| author_facet | Mariana J Kaplan |
| author_sort | Mariana J Kaplan |
| collection | DOAJ |
| description | Mariana J KaplanDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USAAbstract: Psoriasis is associated to an increased risk of cardiovascular (CV) complications. Overall, the pathogenic mechanisms involved in premature CV complications in psoriasis appear to be complex and multifactorial, with traditional and nontraditional risk factors possibly contributing to the increased risk. Based on what is known about the pathogenesis of psoriasis and extrapolating the current knowledge on CV complications in other inflammatory diseases, studies are needed to investigate if appropriate control of the inflammatory, immunologic and metabolic disturbances present in psoriasis can prevent the development of this potentially lethal complication. It is clear that there is a great need for heightened awareness of the increased risk for vascular damage in patients with psoriasis. It is also crucial to closely monitor patients with psoriasis for CV risk factors including obesity, hypertension, diabetes, and hyperlipidemia. Whether treatment regimens that effectively manage systemic inflammation will lead to prevention of CV complications in psoriasis needs to be investigated. Clearly, studies should focus on establishing the exact mechanisms that determine CV risk in psoriasis so that appropriate preventive strategies and treatment guidelines can be established.Keywords: psoriasis, atherosclerosis, inflammation, vascular |
| first_indexed | 2024-12-23T11:58:05Z |
| format | Article |
| id | doaj.art-ad7b2ecbe3f6422989765d208133cd5c |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-23T11:58:05Z |
| publishDate | 2008-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-ad7b2ecbe3f6422989765d208133cd5c2022-12-21T17:48:02ZengDove Medical PressVascular Health and Risk Management1178-20482008-12-01Volume 4122912352018Cardiometabolic risk in psoriasis: differential effects of biologic agentsMariana J KaplanMariana J KaplanDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USAAbstract: Psoriasis is associated to an increased risk of cardiovascular (CV) complications. Overall, the pathogenic mechanisms involved in premature CV complications in psoriasis appear to be complex and multifactorial, with traditional and nontraditional risk factors possibly contributing to the increased risk. Based on what is known about the pathogenesis of psoriasis and extrapolating the current knowledge on CV complications in other inflammatory diseases, studies are needed to investigate if appropriate control of the inflammatory, immunologic and metabolic disturbances present in psoriasis can prevent the development of this potentially lethal complication. It is clear that there is a great need for heightened awareness of the increased risk for vascular damage in patients with psoriasis. It is also crucial to closely monitor patients with psoriasis for CV risk factors including obesity, hypertension, diabetes, and hyperlipidemia. Whether treatment regimens that effectively manage systemic inflammation will lead to prevention of CV complications in psoriasis needs to be investigated. Clearly, studies should focus on establishing the exact mechanisms that determine CV risk in psoriasis so that appropriate preventive strategies and treatment guidelines can be established.Keywords: psoriasis, atherosclerosis, inflammation, vascularhttps://www.dovepress.com/cardiometabolic-risk-in-psoriasis-differential-effects-of-biologic-age-peer-reviewed-article-VHRMPsoriasisatherosclerosisinflammationvascular. |
| spellingShingle | Mariana J Kaplan Cardiometabolic risk in psoriasis: differential effects of biologic agents Vascular Health and Risk Management Psoriasis atherosclerosis inflammation vascular. |
| title | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| title_full | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| title_fullStr | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| title_full_unstemmed | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| title_short | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| title_sort | cardiometabolic risk in psoriasis differential effects of biologic agents |
| topic | Psoriasis atherosclerosis inflammation vascular. |
| url | https://www.dovepress.com/cardiometabolic-risk-in-psoriasis-differential-effects-of-biologic-age-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT marianajkaplan cardiometabolicriskinpsoriasisdifferentialeffectsofbiologicagents |